Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer’s Gilotrif/Giotrif, but the new asset is far behind competitors from AstraZeneca and Clovis.